Table 3.
3-month follow-up n = 76 | 12-month follow-up n = 63e,f | Last follow-up n = 76 | ||||||
---|---|---|---|---|---|---|---|---|
3.1 months (2.7–3.8) | 12 months (11.1–13.3) | 4.7 years (2.2–9.2) | ||||||
Early-bioa | No early-biob | Early- bioa | No early-biob | Early-bioa | No early-biob | |||
Clinically inactive diseasec | 23/40 (58%) | 21/36 (58%) | 26/29e (90%) | 18/34f (53%) | 36/40 (90%) | 31/36 (86%) | ||
ns | p = 0.002 | ns | ||||||
Treatment-free clinically inactive disease (remission) | 1/40 (3%) | 2/36 (6%) | 0/29 (0%) | 3/34 (9%) | 8/40 (20%) | 16/36 (42%) | ||
ns | ns | p = 0.028 | ||||||
Glucocorticoid-free clinically inactive diseased | 7/40 (18%) | 7/36 (19%) | 20/29 (69%) | 16/34 (47%) | 34/40 (85%) | 30/36 (83%) | ||
ns | ns | ns |
Median age presented along with interquartile range (IQR). Absolute frequencies presented along with percentages.
Patients who received either IL-1 or IL-6 blockade within 3 months from diagnosis.
Patients who did not receive IL-1 or IL-6 blockade within 3 months from diagnosis (irrespective of whether they received those treatments after this time point).
CID irrespective of current treatment status.
CID, off glucocorticoids (irrespective of other treatments received).
Missing data, n = 1; time point not reached n = 9.
Missing data, n = 2; time point not reached n = 1. ns (not significant) at p < 0.05 using Fisher's exact test. Shaded cells denote significantly different comparisons.